


EVEREST MEDICINES
云 頂 新 耀
Everest Medicines Limited
雲 頂 新 耀 有 限 公 司
(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號: 1952)

24 April 2026

Dear registered shareholder(s),

Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1)

With reference to the notification letter dated 6 September 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", Everest Medicines Limited (the "Company") is writing to remind you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"). Corporate communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.everestmedicines.com and the website of HKEx at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

Pursuant to Rule 2.07A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Company shall despatch to you by electronic means or by post the Actionable Corporate Communications^(Note 2). The Company has not received your email address for the electronic dissemination of Corporate Communications. To ensure timely receipt of the Actionable Corporate Communications^(Note 2), the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Hong Kong Share Registrar, the Company will send the Actionable Corporate Communications^(Note 2) in printed form to you in the future.

If you want to receive the future Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Hong Kong Share Registrar or send an email to everestmedicines.ecom@computershare.com.hk specifying your name, address and request to receive the future Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Please be reminded that provision of your correct and effective contact details (including email address and mailing address) to the Company and/or the Hong Kong Share Registrar is critically important, and any mistakes in such details may result in failure of delivery of the Company's Corporate Communications and/or Actionable Corporate Communications to you timely in the future.

Should you have any queries relating to this letter, please send an email to the Hong Kong Share Registrar at everestmedicines.ecom@computershare.com.hk.

Yours faithfully,
By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Note:

- This letter is addressed to registered shareholders of the Company who have not yet provided an email address for the timely receipt of actionable corporate communications. If you are a new registered shareholder, please read the arrangement for the electronic dissemination of corporate communications below and provide your email address as recommended.
- Actionable Corporate Communication is any corporate communication that seeks instructions from Company's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東：

有關以電子方式發布公司通訊安排的提示信 (附註1)

根據日期為2024年9月6日有關「以電子方式發布公司通訊之安排」之通知信函所述，雲頂新耀有限公司（「本公司」）謹此提醒閣下，本公司已採用以電子方式發布公司通訊（「公司通訊」）之安排。公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a)董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b)中期報告及其中期報告摘要（如適用）；(c)會議通知；(d)上市文件；(e)通函；和(f)委任代表表格。

請注意，所有未來公司通訊的英文版和中文版將在本公司網站 www.everestmedicines.com 和香港交易所網站 www.hkexnews.hk 上提供，以代替印刷本。

徵集電子聯絡資料

根據香港聯合交易所有限公司證券上市規則第2.07A條，本公司須向閣下以電子方式或者郵寄方式寄送可供採取行動的公司通訊^(附註2)。本公司尚未收到閣下就接收公司通訊提供電子郵件地址。為確保及時收到可供採取行動的公司通訊^(附註2)，本公司建議閣下透過掃描本函背頁之回條（「回條」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回香港股份過戶處香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓。

如果本公司沒有收到閣下的有效電子郵件地址，直至香港股份過戶處收到閣下有效的電子郵件地址前，本公司未來將以印刷本形式發送可供採取行動的公司通訊^(附註2)。

若閣下希望收取公司通訊之印刷版，請填妥本函背頁之回條並交回香港股份過戶處，或發送電子郵件至 everestmedicines.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效，此後將過期。

本公司謹此提醒閣下，向本公司及/或港股股份過戶處提供閣下正確及有效的联系方式（包括電子信箱及聯系地址等）至關重要，任何資料錯誤可能導致閣下無法及時接收本公司發佈的公司通訊及/或可供採取行動的公司通訊（視實際情況而定）。

如閣下對本函件有任何疑問，請發送電子郵件至 everestmedicines.ecom@computershare.com.hk 與香港股份過戶處聯絡。

承董事會命
雲頂新耀有限公司
主席兼執行董事
吳以芳
謹啟

2026年4月24日

附註：

- 此函件致尚未提供電子郵件地址以接收可供採取行動的公司通訊之公司登記股東。若閣下為新登記股東，請閱讀以下以電子方式發布公司通訊的安排，並按建議提供閣下的電子郵件地址。
- 可供採取行動的公司通訊指任何涉及要求公司的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

